Skip to content
Back
  • Home
  • About us
    • Company focus
    • Management
    • Board
    • Team
    • Scientific advisory board
    • Partnerships
    • Investors
  • Our science
    • R&D Focus
    • R&D Levers
  • Pipeline
    • Pipeline
    • JM-010
    • CP-012
    • Discovery
  • News
    • Press releases
    • Upcoming events
  • Contact
    • Business Development
    • Social network

Current
Pipeline

See our pipeline

 Link to our ongoing European clinical Ph IIb trial in Parkinson´s disease dyskinesia (NCT03956979)

JM-010

About JM-010

Parkinson’s disease is a common neurological disorder caused by the progressive degeneration of neurons producing dopamine. Standard of care in Parkinson’s disease is treatment with dopamine replacement therapies such as Levodopa or dopamine agonists. However, in advanced stages of Parkinson’s disease, patients treated with dopamine replacement therapies often suffer from dyskinesia, a condition that strongly impacts quality of life and in severe cases can be life-threatening. By applying the basic principles fundamental to our PRECISION MEDICINE methodology, JM-010 was developed as an innovative approach to accelerate the development of new treatment options for Parkinson’s disease patients suffering from dyskinesia.

JM-010 acts as a dual molecular switch by which the target efficacies of two existing and safe medications are perfectly fine-tuned to effectively treat the disease. Using a proprietary formulation, JM-010 targets central mechanisms underlying the development of dyskinesia in Parkinson’s disease. JM-010 has successfully demonstrated its efficacy and safety in preclinical studies, as well as in Ph1 clinical safety and Ph2 clinical proof of concept studies. Currently, JM-010 is undergoing Ph2 clinical studies in Europe and US.

CP-012

About CP-012

Levodopa is the gold-standard for treatment in Parkinson`s disease, but patients often need to administer up to 6-8 doses daily due to its short half-life and wearing-off. Since frequent dosing is not possible at nighttime, around 60% of patients suffer from disabling nocturnal and early morning muscle stiffness known as early morning akinesia. Furthermore, patients may experience a delayed onset of action with the first morning dose of Levodopa, which increases and extends their morning disability. There is currently no efficient therapy available for early morning akinesia.

We are developing CP-012 in collaboration with BDD Pharma as a novel formulation of levodopa and carbidopa to be taken ad bedtime in addition to normal medication and prevent the onset of nocturnal symptoms and early morning akinesia. Contera Pharma has full ownership and holds global rights to the program.

Neuroinflammation

About Neuroinflammation

Recent clinical and preclinical studies point towards a critical role for neuroinflammation in the development of movement disorders including Parkinson’s disease. With the University of Copenhagen, we investigate glial biology involvement in disease by utilizing state-of-the-art bioengineering tools to enable the identification of novel drug targets for us to pursue in our continued efforts to develop better treatment options for patients.

Discovery

Work in progress

Recent News

September 27, 2022
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology
Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”)…
Read more
September 08, 2022
Contera Pharma signs agreement with BDD Pharma for development of a novel tablet formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, has entered into collaboration with BDD Pharma, a drug delivery…
Read more

View all news

Contact us

Denmark map icon

Contera Pharma Headquarter

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

Thomas Sager, CEO
info@conterapharma.com

South Korea map icon

Contera Pharma Korea

7, SangDo-Ro, Dongjak-Gu
Seoul, 06955
Korea

info@conterapharma.com

Contact us

Contera Pharma Headquarter

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

 

Thomas Sager, CEO

info@conterapharma.com

Contera Pharma Korea

7, SangDo-Ro,

Dongjak-Gu

Seoul, 06955

Korea

info@conterapharma.com

Connect on Linkedin

Useful links

About us

Our Science

Pipeline

News

Contact

Cookie policy

Privacy policy

Bukwang

Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years.

Discover Bukwang

Designet af Standoutmedia